Re: EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study

J wrote:

<
http://money.cnn.com/news/newsfeeds/articles/prnewswire/NEW01424102007-1.htm

EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
Results Demonstrate Activity in Advanced Disease
October 24, 2007: 07:00 AM EST

ROCKVILLE, Md., Oct. 24 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of cancer and inflammatory diseases, today announced the
presentation of results for its Phase 2, open-label study for Panzem(R)
NCD (2ME2 or 2-methoxyestradiol) in patients with ovarian cancer. The
results were presented by Dr. Daniela Matei, principal investigator for
the study representing the Hoosier Oncology Group, at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics
being held this week in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Data from the Phase 2 study demonstrate that Panzem(R) NCD, administered
as a single agent in patients with platinum refractory epithelial ovarian
cancer, resulted in one patient with a confirmed partial response of their
CA- 125. Five patients, out of the 18 patients enrolled, achieved stable
disease lasting greater than three months. Panzem(R) NCD was well
tolerated and no significant neuropathy, myelosuppression or
thromboembolic side effects were reported. Three patients remained on
study for more than 6 months and two of these patients are still on study.

8 studies were found.

http://clinicaltrials.gov/ct/show/NCT00030095
1. Completed 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific

http://clinicaltrials.gov/ct/show/NCT00028821
2. Completed 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Unspecified Adult Solid
Tumor, Protocol Specific

http://clinicaltrials.gov/ct/show/NCT00306618
3. Active, not recruiting Safety and Efficacy Study of Panzem NCD to Treat
Glioblastoma
Condition: Recurrent Glioblastoma Multiforme

http://clinicaltrials.gov/ct/show/NCT00328497
4. Active, not recruiting A Combination Study to Determine the Safety and
Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Condition: Carcinoid Tumor

http://clinicaltrials.gov/ct/show/NCT00444314
5. Recruiting Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib
Malate in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma

http://clinicaltrials.gov/ct/show/NCT00394810
6. Active, not recruiting Efficacy and Pharmacodynamic Study of Panzem® NCD in
Patients With Hormone-Refractory Prostate Cancer
Condition: Prostate Cancer

http://clinicaltrials.gov/ct/show/NCT00400348
7. Active, not recruiting Safety and Efficacy Study of Panzem® Nanocrystal
Colloidal Dispersion in Patients With Ovarian Cancer
Condition: Ovarian Cancer

http://clinicaltrials.gov/ct/show/NCT00481455
8. Recruiting Phase 2 Study of Panzem NCD in Combination With Fixed-Dose
Temozolomide to Patients With Recurrent GBM
Condition: Recurrent Glioblastoma Multiforme

.

Relevant Pages

  • Conversations with a quack.
    ... I would be surprised if you could not, by sifting through a thousand odd cases over many years, find some cases with unexpected outcomes, such as these with ovarian cancer. ... I am dismayed also that your clinic is sifting through old cases to try and find good ones, instead of prospectively showing a treatment effect of Gerson in new patients with measurable cancer, in a well-planned study, as I have suggested. ... Not only that, but you wish to enter into argument with someone who has been studying it, and also alternative methods, quite intensively. ...
    (misc.health.alternative)
  • Re: A message for Peter Moran, et al
    ... natural cures is due to monetary greed...although certainly the ... to maim patients for their money. ... Every cancer doctor hopefully has one patient he ... of practice...so he went to see Revici himself to find out what was ...
    (misc.health.alternative)
  • Safety of Antioxidants During GYN Cancer Care
    ... Safety of Antioxidants During GYN Cancer Care ... This study is currently recruiting patients. ... Sponsored by: University of Kansas ...
    (sci.med.diseases.cancer)
  • Treatment and the age factor
    ... Like any case of stage 2 breast cancer, ... But Caldwell faced another reality?her age: ... That surge in patients, physicians say, will likely outpace the knowledge ... most chemotherapy and other research trials generally include ...
    (sci.med.diseases.cancer)
  • Re: The cancer discussion continues
    ... the foreword to the book "The Man Who Cures Cancer." ... the tactic has been to whinge and whine about the doctors. ... Revici had more terminal patients cured than every doctor in the US ...
    (misc.health.alternative)